Home › Research › Cognitive tests and assessment
Effect of TTP488 in patients with mild to moderate Alzheimer's disease
Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM.. BMC neurology, 2014-01-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background TTP488, an antagonist at the Receptor for Advanced Glycation End products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488. Acute, reversible cognitive worsening was seen with a 20 mg/day dose.
What this study adds
Evidence grade: High
This is a trial of 399 participants. This trial tested the drug TTP488 in 399 patients with mild to moderate Alzheimer's disease. It does not report that TTP488 cures or prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Burstein, A. H., Grimes, I., Galasko, D. R., Aisen, P. S., Sabbagh, M., & Mjalli, A. M. (2014). Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC neurology. https://doi.org/10.1186/1471-2377-14-12
Vancouver
Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC neurology. 2014. doi:10.1186/1471-2377-14-12. PMID: 24423155.
BibTeX
@article{burstein2014-24423155,
author = {Burstein, A. H. and Grimes, I. and Galasko, D. R. and Aisen, P. S. and Sabbagh, M. and Mjalli, A. M.},
title = {{Effect of TTP488 in patients with mild to moderate Alzheimer's disease}},
journal = {BMC neurology},
year = {2014},
doi = {10.1186/1471-2377-14-12},
pmid = {24423155},
url = {https://doi.org/10.1186/1471-2377-14-12}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- A previous report describes decreased decline in ADAS-cog (delta = 3.1, p = 0.008 at 18 months, ANCOVA with multiple imputation), relative to placebo, following a 5 mg/day dose of TTP488.
- Acute, reversible cognitive worsening was seen with a 20 mg/day dose.
- The present study further evaluates the efficacy of TTP488 by subgroup analyses based on disease severity and concentration effect analysis.
- Methods 399 patients were randomized to one of two oral TTP488 doses (60 mg for 6 days followed by 20 mg/day; 15 mg for 6 days followed by 5 mg/day) or placebo for 18 months.
Why it matters
This trial tested the drug TTP488 in 399 patients with mild to moderate Alzheimer's disease. It does not report that TTP488 cures or prevents Alzheimer's disease.
Study details
- Study designclinical trial
- Participants399
- Evidence strengthHigh
How this study scored 65/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (BMC neurology) |
| Journal's citation record | 1 / 4 | BMC Neurology: journal h-index 122 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 399 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 5 / 7 | Cited 136 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 9.7 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 3 / 6 | Cited 7.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 3 other studies in this library |
| Still being cited | 2 / 4 | Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Adnan M.M. Mjalli: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California San Diego: institution h-index 1,852 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | PubMed indexes it as a multicentre study |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24423155) |
| Free to read | 2 / 2 | Free to read |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
3 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.